

Studies to promote regionally

**TRITON 3**

A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency

PI – Dr John Graham (TST)

*NB: This study has a high screen failure rate as patients are required to have multiple genetic markers.*

**CA209-9ER: Advanced or Metastatic Renal Cell Carcinoma**

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

PI – Dr John McGrane (RCHT)

**Erdaftinib compared with Vinflunine or Docetaxel or Pembrolizumab**

A Phase 3 Study of Erdaftinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

PI Dr Pete Sankey (UHPNT)

**RE-AKT**

A randomised Phase II study of Enzalutamide (MDV3100) in combination with AZD5363 in Patients with Metastatic Castration Resistant Prostate Cancer

PI Dr Pete Sankey (UHPNT)

**UK P3BEP Trial**

A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

PI Dr Pete Sankey (UHPNT)

**ATLANTIS**

An adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in metastatic urothelial cancer

PI – Dr Mohini Varughese (TST)

PI – Prof Syed Hussain (UNPNT)

**NEPTUNES**

Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature

PI – Prof Syed Hussain (UHPNT)